San Diego biotech Glycoregimmune is working on a way to inhibit the natural killer T cells that exacerbate the inflammatory response and hepatic injury that stems from liver disease.
Natural killer T cells are a sort of heterogenous variety of immune cell; the company says:
NKT cells share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 NKT cells play a critical role in initiating and propagating the inflammatory response and the hepatic injury that is observed in liver disease. GRI’s lead program, GRI-0621, is an inhibitor of type I NKT cells and is being developed as a novel oral therapeutic for acute liver failure.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The immunotherapy biotech just raised $4.3 million, according to a regulatory filing. The research comes from Torrey Pines Institute for Molecular Studies.
Its lead program, the oral drug GRI-0621, is in the midst of early clinical studies among chronic liver disease patients.